Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Company Overview - Axogen, Inc. (NASDAQ:AXGN) is a leader in developing and marketing surgical solutions for peripheral nerve injuries [3] - The company focuses on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair [3] - Axogen aims to restore peripheral nerve function and improve the quality of life for patients with nerve damage through innovative and clinically proven solutions [3] Product Portfolio - Axogen's product offerings include Avance® nerve graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, and Axoguard Nerve Cap® [5] - The products are designed for two main application categories: scheduled non-trauma procedures and emergent trauma procedures [4] - The portfolio is available in multiple countries, including the United States, Canada, Germany, the United Kingdom, Spain, and South Korea [5] Upcoming Financial Results - Axogen will report its 2023 fourth quarter and full-year financial results on March 5, 2024, before the market opens [1] - Following the release, management will host a conference call and webcast at 8 a.m. ET [1] - Investors can participate in the conference call via phone or listen live on the company's website [1][2]